US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology
Amgen has licensed ImmunoGen's Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics for an undisclosed amount. ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing ...
Tags: anticancer therapeutics, healthcare companies, healthcare, ImmunoGen
The Canadian Intellectual Property Office has issued a patent for Lorus Therapeutics' cancer immunotherapy agent, IL-17E. The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, ...
Tags: patent, IL-17E, treatment of cancer